Our passion is to develop important, disease-modifying therapies for devastating pulmonary diseases – and Cystic Fibrosis is the first target on our list.

We are building a dedicated team of scientists, clinical staff, management and advisors with the skills and vision to make this a reality.

Tim Shannon, MD


Dr. Shannon is a board-certified pulmonologist with multidisciplined experience in research, strategic drug development, and medical and clinical affairs, including prior roles in industry, academia, and clinical practice. He is a General Partner in the healthcare practice at Canaan Partners focused on early-stage investing. In this role, he was the founding CEO of Canaan portfolio companies Arvinas and Aldea and sits on the boards of IDEAYA Biosciences, Nextcure, Arvinas (Chair), and Vivace Therapeutics.

Previous to joining Canaan, Dr. Shannon was President and CEO of CuraGen, a publicly traded biopharmaceutical company. Earlier, he was Senior Vice President of Global Medical and Clinical Development for Bayer Pharmaceuticals, responsible for all strategic and operational aspects of clinical development and drug safety. Prior to his career in industry, Dr. Shannon was an Assistant Professor in the Pulmonary and Critical Care Division at Yale University School of Medicine and an Attending Physician in Pulmonary and Critical Care Medicine at the West Haven VA Medical Center.

Dr. Shannon received his postgraduate medical training at the Beth Israel Hospital of Harvard Medical School and Boston University. He earned his medical degree from the University of Connecticut and has a BA in Chemistry from Amherst College.

Timm Crowder, PhD

Chief Operating Officer

Timm has 20 years of experience in pharmaceutical operations, manufacturing and respiratory product development. He came to Spyryx from GlaxoSmithKline where he was most recently Director of Advanced Manufacturing Technology, leading innovation in the areas of aerosol and dry powder inhaler release testing, technology enhanced manufacturing, electronic inhaler and particle engineering technologies. Earlier in his tenure at GSK, he contributed to the development of manufacturing systems and quality-by-design for GSK’s current asthma and COPD products.

Prior to GSK, Timm was co-founder and Chief Technology Officer of Oriel Therapeutics, an inhaler technology company launched to commercialize a dry powder inhaler he developed during his graduate research. Oriel was subsequently acquired by Sandoz Pharmaceuticals.

Timm earned his PhD in Biomedical Engineering from UNC-Chapel Hill and has degrees in Physics from North Carolina State University and Davidson College. He is an inhalation and manufacturing technology expert credited with 10 issued patents on inhalers and powder filling systems and more than 25 publications, book chapters and international presentations relating to aerosol drug delivery, inhaler design, powder filling, and product formulation and characterization.